What Is Ivermectin?
Ivermectin is a small organic compound originally derived from the soil bacterium Streptomyces avermitilis. First discovered in Japan during the 1970s, the drug quickly became one of the most important antiparasitic medicines ever developed.
Its impact on global health was so significant that researchers Satoshi Ōmura and William C. Campbell were awarded the 2015 Nobel Prize in Physiology or Medicine for their work related to its discovery and development.
Ivermectin was approved for veterinary use in 1981 and later approved for human use in 1987. Today, it is available in several forms, including oral tablets and topical creams.
Why Is Ivermectin So Widely Used?
For decades, ivermectin has been used to treat a range of parasitic infections in both humans and animals. Its effectiveness, affordability, and relatively favorable safety profile have made it one of the most widely distributed medicines in public health programs worldwide.
Researchers have also investigated whether ivermectin could have benefits beyond parasite treatment, including applications in dermatology, infectious diseases, inflammation, and cancer research.
How Do Scientists Evaluate Ivermectin?
Individual clinical trials provide valuable information about a drug's effectiveness, but the strongest medical recommendations often come from systematic reviews.
Organizations such as the Cochrane Collaboration evaluate all available clinical evidence on a treatment. These reviews combine data from multiple studies, assess study quality, identify potential bias, and provide evidence-based conclusions.
This process helps researchers and healthcare professionals determine where a drug is effective and where more research is needed.
Ivermectin for Parasitic Worm Infections
Ivermectin is widely used to treat several parasitic worm infections, including:
- Strongyloides stercoralis
- Ascaris lumbricoides
- Wuchereria bancrofti
- Brugia malayi
Studies have shown that ivermectin is highly effective against many of these parasites and remains a cornerstone treatment in global parasite-control programs.
For some infections, ivermectin performs as well as or better than alternative medications while maintaining a favorable safety profile.
Ivermectin and Rosacea
Rosacea is a chronic inflammatory skin condition that causes redness, bumps, and visible blood vessels on the face.
Clinical studies have found that topical ivermectin can significantly reduce inflammatory lesions associated with rosacea. In several trials, it performed better than placebo treatments and showed slightly greater effectiveness than some standard therapies.
As a result, ivermectin cream has become a commonly prescribed treatment option for moderate inflammatory rosacea.
Ivermectin and Scabies
Scabies is caused by microscopic mites that burrow into the skin, producing intense itching and irritation.
Research has shown that ivermectin can effectively treat scabies when taken orally or applied topically. While some studies suggest that permethrin cream remains the most effective first-line treatment, ivermectin continues to be an important option, especially in large outbreaks or when topical treatments are impractical.
Ivermectin and Cancer Research
In recent years, scientists have investigated ivermectin for potential anticancer properties.
Laboratory studies have suggested that ivermectin may:
- slow cancer cell growth
- induce programmed cell death (apoptosis)
- influence tumor-related signaling pathways
- affect cancer cell metabolism
These findings have generated interest in drug repurposing, where existing medications are evaluated for new therapeutic applications.
However, most evidence currently comes from cell culture and animal studies. Large human clinical trials are still lacking, and ivermectin is not an approved cancer treatment.
Ivermectin and COVID-19
During the COVID-19 pandemic, ivermectin became the subject of intense scientific and public interest.
Multiple clinical studies and evidence reviews evaluated whether ivermectin could prevent infection or improve outcomes in patients with COVID-19.
Current evidence has not demonstrated a clear clinical benefit for either prevention or treatment of COVID-19. Health authorities and evidence-review organizations continue to recommend treatments supported by stronger clinical data.
